Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • Ranibizumab and MMCRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)

Phase Distribution

Phase 1/2
1
100%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 1/2Combined phases
1(100.0%)

Highest Phase Reached

Phase 1/2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

1

all time

Status Distribution
Completed(1)

Detailed Status

Completed1

Development Timeline

Analytics

Development Status

Total Trials
1
Active
0
Success Rate
100.0%
Most Advanced
Phase 1/2

Trials by Phase

Phase 1/21 (100.0%)

Trials by Status

completed1100%

Recent Activity

0 active trials
Showing 1 of 1
completedphase_1_2

Use of Ranibizumab With Mitomycin C During Trabeculectomy

NCT00661583

Clinical Trials (1)

Showing 1 of 1 trials
NCT00661583Phase 1/2

Use of Ranibizumab With Mitomycin C During Trabeculectomy

Completed

All 1 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
1